Prelude Therapeutics Inc (PRLD)
$2
+0.11
(+5.82%)▲
Performance
- $1.88$2.05$2.00
6.0%
Downside
Day's Volatility :8.07%
Upside
2.2%
- $1.66$6.80$2.00
17.0%
Downside
52 Weeks Volatility :75.59%
Upside
70.59%
Returns
| Period | Prelude Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -45.22% | 4.9% | 0.0% |
6 Months | -59.79% | 5.8% | 0.0% |
1 Year | -29.74% | 16.5% | 0.0% |
3 Years | -93.43% | 20.3% | -20.1% |
Highlights
Market Capitalization | 113.4M |
Book Value | $3.31 |
Earnings Per Share (EPS) | -1.77 |
Wall Street Target Price | 5.8 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -35.22% |
Return On Equity TTM | -58.45% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -140.8M |
Diluted Eps TTM | -1.77 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.83 |
EPS Estimate Next Year | -1.6 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.43 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 190.0%
Technicals Summary
Sell
Neutral
Buy
Prelude Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Prelude Therapeutics Inc | -61.03% | -59.79% | -29.74% | -93.43% | -92.79% |
 Regeneron Pharmaceuticals, Inc. | -10.33% | 8.11% | 21.28% | 85.63% | 257.49% |
 Novo Nordisk A/s | -12.25% | -9.71% | 24.92% | 138.38% | 343.21% |
 Alnylam Pharmaceuticals, Inc. | 9.22% | 72.73% | 52.35% | 34.04% | 250.13% |
 Vertex Pharmaceuticals Incorporated | -3.09% | 12.2% | 25.77% | 150.7% | 163.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Prelude Therapeutics Inc | NA | NA | NA | -1.83 | -0.58 | -0.35 | NA | 3.31 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Prelude Therapeutics Inc | Sell | $113.4M | -92.79% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 257.49% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 343.21% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 250.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.62% | 32.84 | -4.74% |
Insights on Prelude Therapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 52.3% return, outperforming this stock by 82.0%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 34.0% return, outperforming this stock by 127.4%
Institutional Holdings
Orbimed Advisors, LLC
19.83%Baker Bros Advisors LP
18.40%Deerfield Management Co
7.51%Boxer Capital LLC
4.67%BlackRock Inc
1.94%Vanguard Group Inc
1.84%
Company Information
prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.
Organization | Prelude Therapeutics Inc |
Employees | 128 |
CEO | Dr. Krishna Vaddi D.V.M., Ph.D. |
Industry | Health Technology |
Discover More
Eagle Pharmaceuticals Inc.
$2.00
+5.82%
Graniteshares 2x Long Baba Daily Etf
$2.00
+5.82%
Mingteng International Corp Inc
$2.00
+5.82%
Direct Digital Holdings Inc
$2.00
+5.82%
Dt Cloud Star Acquisition Corporation Right
$2.00
+5.82%
Precipio Inc
$2.00
+5.82%
Venus Concept Inc
$2.00
+5.82%
Fidelity Msci Materials Etf
$2.00
+5.82%
Inspire International Etf
$2.00
+5.82%